Samsung Bioepis Builds Its Biosimilars Name In Europe
Executive Summary
EU clearance of Samsung Bioepis' Imraldi, its adalimumab biosimilar, is the South Korean firm's third biosimilar anti-TNF alpha product to get approval in Europe.
You may also be interested in...
US Approvals Roundup: Cyltezo Biosimilar, Victoza CV Benefit, Gocovri In PD, Kedrab Rabies Biologic, Gout Combo Duzallo
FDA's clearances showcase the application of formulation technology to reduce problem side effects and improve convenience of available drugs.
Remicade: Biosimilars And Pricing Pressure Wear On J&J's Blockbuster Brand
US sales were down 14%, but much of the hit was due to a 2016 price adjustment that was felt across the pharma portfolio, and execs insisted the impact of biosimilars is more moderate than expected.
EU CHMP OKs Imraldi, Samsung Bioepis’ Biosimilar Of AbbVie’s Humira
The EU’s CHMP has given the green light to Imraldi, Samsung Bioepis’ biosimilar version of AbbVie’s blockbuster adalimumab product Humira. If approved by the European Commission, this will be the South Korean company’s third biosimilar anti-TNF alpha product to gain a marketing authorization in the EU.